Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.6730
+0.0351 (5.50%)
At close: Sep 15, 2026, 4:00 PM EDT
0.6594
-0.0136 (-2.02%)
After-hours: Sep 15, 2026, 7:36 PM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
n/a
Profits / Employee
-$3,595,486
Market Cap
163.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| Immunic | 100 |
| Tenaya Therapeutics | 70 |
| Corbus Pharmaceuticals Holdings | 36 |
| Jyong Biotech | 27 |
| Spruce Biosciences | 22 |
OTLK News
- 4 days ago - Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - GlobeNewsWire
- 4 days ago - Outlook Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 days ago - Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment - GlobeNewsWire
- 19 days ago - Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed - TheFly
- 19 days ago - Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - GlobeNewsWire
- 19 days ago - Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics announces common stock, warrants offering - TheFly
- 4 weeks ago - Outlook Therapeutics $100M Spot Secondary re-offered at 99c - TheFly